APA (7th ed.) Citation

R, W., DG, S., MB, L., A, S., M, Z., E, M., . . . B, R. (2020). Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study. The oncologist, 25(8), e1158. https://doi.org/10.1634/theoncologist.2020-0039

Chicago Style (17th ed.) Citation

R, Wesolowski, et al. "Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study." The Oncologist 25, no. 8 (2020): e1158. https://doi.org/10.1634/theoncologist.2020-0039.

MLA (9th ed.) Citation

R, Wesolowski, et al. "Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study." The Oncologist, vol. 25, no. 8, 2020, p. e1158, https://doi.org/10.1634/theoncologist.2020-0039.